Niklas Norén
Niklas Norén
Chief Science Officer, Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug
Verified email at
Cited by
Cited by
Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers
G Hripcsak, JD Duke, NH Shah, CG Reich, V Huser, MJ Schuemie, ...
Studies in health technology and informatics 216, 574, 2015
Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery
GN Norén, J Hopstadius, A Bate
Statistical methods in medical research 22 (1), 57-69, 2013
Temporal pattern discovery in longitudinal electronic patient records
GN Norén, J Hopstadius, A Bate, K Star, IR Edwards
Data Mining and Knowledge Discovery 20, 361-387, 2010
Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events
GN Norén, A Bate, R Orre, IR Edwards
Statistics in medicine 25 (21), 3740-3757, 2006
A statistical methodology for drug–drug interaction surveillance
GN Norén, R Sundberg, A Bate, IR Edwards
Statistics in medicine 27 (16), 3057-3070, 2008
vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues
T Bergvall, GN Norén, M Lindquist
Drug safety 37, 65-77, 2014
Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase
K Star, GN Norén, K Nordin, IR Edwards
Drug safety 34, 415-428, 2011
Duplicate detection in adverse drug reaction surveillance
GN Norén, R Orre, A Bate, IR Edwards
Data Mining and Knowledge Discovery 14, 305-328, 2007
Good signal detection practices: evidence from IMI PROTECT
AFZ Wisniewski, A Bate, C Bousquet, A Brueckner, G Candore, K Juhlin, ...
Drug safety 39, 469-490, 2016
Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®
RE Chandler, K Juhlin, J Fransson, O Caster, IR Edwards, GN Norén
Drug safety 40, 81-90, 2017
Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank: retrospective evaluation against emerging safety signals
O Caster, K Juhlin, S Watson, GN Norén
Drug safety 37, 617-628, 2014
Large‐scale regression‐based pattern discovery: the example of screening the WHO global drug safety database
O Caster, GN Norén, D Madigan, A Bate
Statistical Analysis and Data Mining: The ASA Data Science Journal 3 (4 …, 2010
Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second‐generation antipsychotics
J de Leon, EJ Sanz, GN Norén, C De las Cuevas
World Psychiatry 19 (1), 120, 2020
Recommendations for the use of social media in pharmacovigilance: lessons from IMI WEB-RADR
J van Stekelenborg, J Ellenius, S Maskell, T Bergvall, O Caster, ...
Drug Safety 42, 1393-1407, 2019
Temporal pattern discovery for trends and transient effects: its application to patient records
GN Norén, A Bate, J Hopstadius, K Star, IR Edwards
Proceedings of the 14th ACM SIGKDD international conference on Knowledge …, 2008
Impact of stratification on adverse drug reaction surveillance
J Hopstadius, GN Norén, A Bate, IR Edwards
Drug safety 31, 1035-1048, 2008
Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest
RD Boyce, PB Ryan, GN Norén, MJ Schuemie, C Reich, J Duke, ...
Drug safety 37, 557-567, 2014
Assessment of the utility of social media for broad-ranging statistical signal detection in pharmacovigilance: results from the WEB-RADR project
O Caster, J Dietrich, ML Kürzinger, M Lerch, S Maskell, GN Norén, ...
Drug safety 41, 1355-1369, 2018
Modern methods of pharmacovigilance: detecting adverse effects of drugs
GN Norén, IR Edwards
Clinical medicine 9 (5), 486, 2009
Performance of stratified and subgrouped disproportionality analyses in spontaneous databases
S Seabroke, G Candore, K Juhlin, N Quarcoo, A Wisniewski, R Arani, ...
Drug safety 39, 355-364, 2016
The system can't perform the operation now. Try again later.
Articles 1–20